Aim of this study was the evaluation of efficacy and tolerability of an add-on rufinamide (RFN) trial in 33 patients with epileptic encephalopathies secondary to complex brain malformations. Patients have been considered responders if seizure reduction was greater than 50%. 19/33 patients (57.6%) are responders: in particular in 9 patients seizure's reduction was greater than 50% and in 10 was greater than 75%. The mean follow-up was 15.1 months (8-36 months). All non-responder patients (42.4%) discontinued rufinamide. 21,2% of subjects presented mild and transient side effects. In one case (3,1%) RFN was discontinued because of persisting anorexia. In a another case RFN was discontinued for an increase of seizures. Our results suggest that rufinamide can be considered as a valuable adjunctive therapeutic option in epileptic encephalopathies secondary to complex brain malformations).
|Translated title of the contribution||Efficacy of Rufinamide in epileptic encephalopathies secondary to complex brain malformations|
|Number of pages||3|
|Journal||Bollettino - Lega Italiana contro l'Epilessia|
|Publication status||Published - Apr 2013|
ASJC Scopus subject areas
- Clinical Neurology